ArticleCancer drug resistance (Alhambra, Calif.)2020

EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer.

Kevin J Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.